Again, courtesy of research analyst Mizohu, is Auvelity compared to other recent Major Depression drug launches. The table is somewhat hard to read, the week 4 change in total prescriptions (TRx's via IQVIA) is 17% w/w change (308 to 360), which is impressive. We will keep tracking Auvelity's launch, but for right now, it's very positive. Again, thanks to Mizuho for the market research. Please click on the table below, for better viewing.
No comments:
Post a Comment